Klow Kpv
Klow KPV refers to laboratory research investigating the anti-inflammatory tripeptide Lysine-Proline-Valine (KPV), a derived C-terminal sequence of alpha-melanocyte-stimulating hormone (α-MSH). Researched primarily for its ability to modulate intracellular inflammatory cascades, downregulate nuclear factor kappa B (NF-κB), and preserve intestinal epithelial barrier integrity, KPV is an essential reference compound in preclinical mucosal immunology.
Quick answer
Klow KPV refers to laboratory research investigating the anti-inflammatory tripeptide Lysine-Proline-Valine (KPV), a derived C-terminal sequence of alpha-melanocyte-stimulating hormone (α-MSH). Researched primarily for its ability to modulate intracellular inflammatory cascades, downregulate nuclear factor kappa B (NF-κB), and preserve intestinal epithelial barrier integrity, KPV is an essential reference compound in preclinical mucosal immunology.
Key takeaways
- In biomedical research literature, klow [kpv](/research-peptides/kpv) represents the synthesized tripeptide sequence Lysine-Proline-Valine (Lys-Pro-Val or KPV), which corresponds to the C-terminal amino acid sequence (residues 11–13) of the endogenous neuropeptide alpha-melanocyte-stimulating hormone (α-MSH).
- The primary mechanism by which [KPV](/research-peptides/kpv) exerts anti-inflammatory effects in cellular assays involves the inhibition of the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) transcription factor complex.
- A critical feature of [KPV](/research-peptides/kpv) in gastroenterology research is its selective uptake across epithelial cells via the Oligopeptide Transporter 1 (PepT1 / SLC15A1).
- The preclinical literature regarding [KPV](/research-peptides/kpv) focuses heavily on animal models of inflammatory bowel disease (IBD), specifically dextran sodium sulfate (DSS)-induced and trinitrobenzene sulfonic acid (TNBS)-induced colitis in rodents.
Definition and Structural Identification of Klow KPV
In biomedical research literature, klow kpv represents the synthesized tripeptide sequence Lysine-Proline-Valine (Lys-Pro-Val or KPV), which corresponds to the C-terminal amino acid sequence (residues 11–13) of the endogenous neuropeptide alpha-melanocyte-stimulating hormone (α-MSH). While α-MSH functions as a non-selective melanocortin receptor agonist with diverse endocrine and anti-inflammatory activity, the truncated tripeptide KPV retains potent anti-inflammatory properties while demonstrating distinct, receptor-independent signaling pathways.
Unlike its full-length parent peptide, KPV does not elicit melanogenesis or activate classical melanocortin receptors (MC1R–MC5R) with high affinity. Instead, researchers utilize KPV tripeptide compounds to study localized cell-entry dynamics, nuclear translocation inhibition, and solute carrier transportation without triggering systemic hormonal signaling pathways. Laboratories evaluating research peptides inspect KPV for its minimalistic structural footprint, low molecular mass (341.41 g/mol), and chemical stability across diverse pH environments.
Molecular Mechanism of Action: NF-κB Pathway Modulation
The primary mechanism by which KPV exerts anti-inflammatory effects in cellular assays involves the inhibition of the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) transcription factor complex. In unstimulated state epithelial cells and macrophages, NF-κB is sequestered in the cytoplasm by inhibitor proteins (IκB). Upon stimulation with pro-inflammatory mediators such as tumor necrosis factor-alpha (TNF-α) or lipopolysaccharide (LPS), IκB undergoes phosphorylation and degradation, allowing NF-κB to translocate into the nucleus and initiate transcription of inflammatory genes.
Preclinical in vitro assays demonstrate that KPV directly modulates this cascade. Fluorescence microscopy and Western blot analyses indicate that KPV entry into the cytoplasm results in diminished phosphorylation of IκB-α, thereby arresting the nuclear translocation of the p65 subunit of NF-κB. Consequently, downstream gene expression of pro-inflammatory cytokines—including Interleukin-1 beta (IL-1β), Interleukin-6 (IL-6), Interleukin-8 (IL-8), and TNF-α—is markedly suppressed. Researchers investigating anti-inflammatory pathways frequently benchmark KPV against broader pathway inhibitors to quantify localized transcriptomic shifts.
Intestinal Epithelial Transporter Interaction: PepT1 Translocation
A critical feature of KPV in gastroenterology research is its selective uptake across epithelial cells via the Oligopeptide Transporter 1 (PepT1 / SLC15A1). PepT1 is a proton-coupled symporter predominantly expressed on the apical membrane of intestinal epithelial cells (enterocytes) and abnormally upregulated in inflamed colonic tissues.
In vitro cellular models utilizing Caco-2 monolayers demonstrate that KPV acts as a high-affinity substrate for PepT1. Upon binding, PepT1 actively facilitates the intracellular influx of KPV across the apical brush border membrane into the cytosol. Once inside the enterocyte, KPV exerts its anti-inflammatory mechanism directly at the intracellular level. This PepT1-dependent transport mechanism allows researchers to examine targeted intracellular peptide delivery, bypassing classical surface receptor requirements. Studies examining gut barrier peptides emphasize the role of PepT1 kinetics in governing KPV cellular accumulation.
Preclinical Literature: Intestinal Barrier Integrity & Colitis Models
The preclinical literature regarding KPV focuses heavily on animal models of inflammatory bowel disease (IBD), specifically dextran sodium sulfate (DSS)-induced and trinitrobenzene sulfonic acid (TNBS)-induced colitis in rodents. In these experimental models, administration of KPV demonstrated significant attenuation of colonic histological damage, reduction of mucosal leukocyte infiltration, and suppression of myeloperoxidase (MPO) activity.
Furthermore, in vitro studies employing electrophysiological measurements (such as Transepithelial Electrical Resistance, or TEER) reveal that KPV helps preserve tight junction protein expression. Exposure of intestinal epithelial monolayers to inflammatory cytokines typically induces the disassembly of zonula occludens-1 (ZO-1) and occludin, leading to hyperpermeability. Preclinical data indicate that co-treatment with KPV mitigates cytokine-induced TEER reduction and maintains structural localization of ZO-1 along the cell border, making it a critical reference compound for barrier function assays.
Comparative Analysis: KPV vs. BPC-157 vs. LL-37 in Epithelial Research
To contextualize the scientific profile of KPV, researchers frequently compare its activity against other prominent mucosal and tissue repair signaling molecules. While KPV primarily targets intracellular NF-κB activation via PepT1 transport, compounds such as BPC-157 operate predominantly through focal adhesion kinase (FAK), VEGFR2 activation, and nitric oxide pathway modulation to accelerate tissue repair and angiogenesis. Conversely, host defense peptides like LL-37 demonstrate direct antimicrobial membrane disruption alongside complex formyl peptide receptor 2 (FPR2) signaling. Meanwhile, tight junction modulators like Larazotide Acetate interact directly with cell-surface receptors to prevent tight junction disassembly without acting as tripeptide substrates.
Understanding these distinct mechanics enables investigators to select appropriate research models depending on whether the experimental endpoint targets transcriptional inflammatory suppression (KPV), vascular repair and cell migration (BPC-157), antimicrobial response (LL-37), or junctional permeability gating (Larazotide).
In Vitro Antimicrobial and Antimycotic Activity
Beyond its anti-inflammatory signaling pathways, preclinical in vitro assays have documented direct antimicrobial and antimycotic properties of KPV, particularly against pathogen species such as *Candida albicans* and *Staphylococcus aureus*. Microdilution assays demonstrate that KPV inhibits *C. albicans* germ tube formation and colony growth at micromolar concentrations.
Mechanistic studies suggest that KPV's antimicrobial action stems from both biophysical interaction with microbial cell walls and intracellular accumulation following peptide translocation. Researchers studying polymicrobial inflammatory environments utilize KPV to evaluate dual-action profiles: simultaneous down-regulation of host cell immune hyper-reactivity and direct suppression of opportunistic pathogen proliferation.
Laboratory Reconstitution and Handling Protocols
To maintain structural integrity and prevent batch-to-batch variability during laboratory testing, KPV must be handled according to strict analytical peptide standards. Lyophilized KPV powder should be stored at -20°C or -80°C in a desiccated environment away from light.
For reconstitution in experimental protocols, researchers should use sterile, bacteriostatic water or sterile phosphate-buffered saline (PBS, pH 7.4). The recommended protocol involves allowing the vial to equilibrate to room temperature prior to reconstitution to minimize moisture condensation inside the vial. Gentle swirling is recommended to achieve complete dissolution; vigorous vortexing or sonication should be avoided as mechanical shear stress can disrupt delicate peptide bonds. Reconstituted aliquots should be stored at -80°C to prevent freeze-thaw degradation cycles.
Analytical Quality Assurance: HPLC, MS, and Endotoxin Verification
Evaluating supplier quality for klow kpv requires verifying comprehensive analytical documentation. Because synthetic peptide impurities (such as truncated sequences, deletion peptides, or residual trifluoroacetate salts) can alter cell culture viability and skew experimental outcomes, strict quality control assays are mandatory.
PX1 Research mandates rigorous batch testing for all compounds. Every lot undergoes Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) to verify chemical purity exceeding 98.0%, and Electrospray Ionization Mass Spectrometry (ESI-MS) to confirm precise molecular mass match. Furthermore, given that KPV is routinely studied in LPS-sensitive and NF-κB cell assays, testing for bacterial endotoxins via Chromogenic Limulus Amebocyte Lysate (LAL) testing is critical. PX1 Research publishes lot-specific Certificate of Analysis (COA) documents for total transparency. Principal investigators interested in high-volume research applications can explore options via our wholesale lab account portal.
Sourcing PX1 Research Peptides: USA Manufacturing & Compliance
PX1 Research serves as a trusted domestic supplier for laboratory reagents and reference compounds. All PX1 products are USA-manufactured in state-of-the-art, ISO 17025-accredited and GMP-compliant facilities. Orders dispatch directly from our CA and AZ logistics hubs, featuring same-day shipping for orders placed Monday through Friday.
Every vial of KPV is distributed strictly for in vitro laboratory research and preclinical testing. PX1 Research enforces strict compliance parameters: our products are not for human consumption, clinical treatment, or diagnostic use. By maintaining complete lot traceability and transparent analytical reporting, PX1 provides the research community with reproducible, reliable tools for cellular and molecular exploration.
Frequently Asked Questions
What is Klow KPV in laboratory research?
Klow KPV refers to the synthetic tripeptide Lysine-Proline-Valine (KPV), derived from the C-terminus of alpha-MSH. It is evaluated in preclinical research for its anti-inflammatory and epithelial barrier-protective properties.
What is the primary mechanism of action of KPV?
Preclinical studies show KPV acts intracellularly by suppressing NF-κB activation, inhibiting IκB-α phosphorylation, and reducing the transcription of pro-inflammatory cytokines like TNF-α, IL-6, and IL-1β.
How does KPV cross cellular membranes in gut models?
KPV is actively transported across intestinal epithelial apical membranes via the Oligopeptide Transporter 1 (PepT1 / SLC15A1) symporter.
What purity standard should be expected for research-grade KPV?
Research-grade KPV should possess a purity of ≥98% as determined by RP-HPLC, with identity confirmed via mass spectrometry (MS) and verified low endotoxin levels.
How should lyophilized KPV be stored upon delivery?
Lyophilized KPV powder should be stored at -20°C or -80°C in a dry environment protected from light to maintain long-term chemical stability.
Is KPV derived directly from full-length alpha-MSH?
KPV represents the C-terminal amino acids 11–13 of alpha-MSH. While synthesized independently for research, its sequence mirrors this natural cleavage fragment.
Can KPV be used in clinical or therapeutic applications?
No. KPV provided by PX1 Research is strictly sold as a reference compound for in vitro laboratory research and preclinical animal models, not for human or veterinary use.
What solvent is recommended for reconstituting KPV for in vitro assays?
Sterile bacteriostatic water or sterile phosphate-buffered saline (PBS, pH 7.4) is typically recommended for reconstitution in laboratory procedures.
Related pages
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.